{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:31:37Z","timestamp":1772915497679,"version":"3.50.1"},"reference-count":21,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: Peroxisome proliferator-activated receptor (PPAR)-\u03b3 agonists have been proposed as therapy to lower plasma ACTH in Cushing\u2019s disease. Cyclical secretion of ACTH may, however, explain some of the responses seen. Patients with Nelson\u2019s syndrome have persistently high levels of ACTH and may be a better model for examining new therapies to elevated ACTH levels.<\/jats:p>\n               <jats:p>Objective: The objective of the study was to assess whether high-dose rosiglitazone therapy reduces circulating ACTH levels in Nelson\u2019s syndrome, a model of ACTH hypersecretion for which no established medical therapy exists.<\/jats:p>\n               <jats:p>Design: The design was an open-label, prospective, nonrandomized study over 14 wk.<\/jats:p>\n               <jats:p>Setting: The study was conducted at a university teaching hospital.<\/jats:p>\n               <jats:p>Patients: Six patients with Nelson\u2019s syndrome participated in the study.<\/jats:p>\n               <jats:p>Methods: Patients were assessed at \u22122, 0, 4, 8, and 12 wk. Rosiglitazone 12 mg\/d was administered between 0 and 8 wk. PPAR-\u03b3 immunoreactivity was assessed in pathological tissue.<\/jats:p>\n               <jats:p>Outcome Measure: Plasma ACTH was measured before (0830 h) and 120 min after morning dosing with hydrocortisone (HC).<\/jats:p>\n               <jats:p>Results: One female withdrew prior to commencing therapy for personal reasons. There was no evidence that ACTH levels changed over time (P = 0.864). The average ACTH level was 1187 ng\/liter (95% confidence interval 928\u20131446) for patients before the HC dose and 432 ng\/liter (95% confidence interval 172\u2013692) after the HC dose. PPAR-\u03b3 immunoreactivity was positive in three ACTH-secreting tumors available.<\/jats:p>\n               <jats:p>Conclusions: Rosiglitazone 12 mg\/d did not change circulating ACTH over time, despite PPAR-\u03b3 receptor expression in the tumor tissue. However, this does not preclude the possibility that other patients may respond or that higher doses of rosiglitazone or more potent agonists might prove useful treatment.<\/jats:p>","DOI":"10.1210\/jc.2006-2005","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T03:56:49Z","timestamp":1172030209000},"page":"1758-1763","source":"Crossref","is-referenced-by-count":37,"title":["Ineffectiveness of Rosiglitazone Therapy in Nelson\u2019s Syndrome"],"prefix":"10.1210","volume":"92","author":[{"given":"A.","family":"Munir","sequence":"first","affiliation":[{"name":"Academic Unit of Diabetes, Endocrinology, and Metabolism (A.M., F.S., R.R., J.N.-P.), The University of Sheffield, Sheffield S10 2JF, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Song","sequence":"additional","affiliation":[{"name":"Academic Unit of Diabetes, Endocrinology, and Metabolism (A.M., F.S., R.R., J.N.-P.), The University of Sheffield, Sheffield S10 2JF, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ince","sequence":"additional","affiliation":[{"name":"Neuropathology (P.I.), The University of Sheffield, Sheffield S10 2JF, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J.","family":"Walters","sequence":"additional","affiliation":[{"name":"School of Medicine and Biomedical Sciences, Medical Statistics Group (S.J.W.), The University of Sheffield, Sheffield S10 2JF, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ross","sequence":"additional","affiliation":[{"name":"Academic Unit of Diabetes, Endocrinology, and Metabolism (A.M., F.S., R.R., J.N.-P.), The University of Sheffield, Sheffield S10 2JF, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Newell-Price","sequence":"additional","affiliation":[{"name":"Academic Unit of Diabetes, Endocrinology, and Metabolism (A.M., F.S., R.R., J.N.-P.), The University of Sheffield, Sheffield S10 2JF, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071614054376800_R1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","article-title":"Cushing\u2019s syndrome.","volume":"367","author":"Newell-Price","year":"2006","journal-title":"Lancet"},{"key":"2020071614054376800_R2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1046\/j.1365-2265.2002.01511.x","article-title":"Long-term follow-up results of transsphenoidal surgery for Cushing\u2019s disease in a single centre using strict criteria for remission.","volume":"56","author":"Rees","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614054376800_R3","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1210\/jc.2005-0070","article-title":"Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas.","volume":"90","author":"Woo","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614054376800_R4","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/nm784","article-title":"Functional PPAR-\u03b3 receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas.","volume":"8","author":"Heaney","year":"2002","journal-title":"Nat Med"},{"key":"2020071614054376800_R5","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1172\/JCI200316575","article-title":"PPAR-\u03b3 receptor ligands: novel therapy for pituitary adenomas.","volume":"111","author":"Heaney","year":"2003","journal-title":"J Clin Invest"},{"key":"2020071614054376800_R6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/eje.0.1510173","article-title":"Effects of chronic administration of PPAR-\u03b3 ligand rosiglitazone in Cushing\u2019s disease.","volume":"151","author":"Ambrosi","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2020071614054376800_R7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2265.2005.02193.x","article-title":"Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing\u2019s syndrome.","volume":"62","author":"Hull","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614054376800_R8","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1210\/jc.2004-1746","article-title":"Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing\u2019s disease.","volume":"90","author":"Suri","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614054376800_R9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11102-005-1403-y","article-title":"The Nelson\u2019s syndrome \u2026 revisited.","volume":"7","author":"Assie","year":"2004","journal-title":"Pituitary"},{"key":"2020071614054376800_R10","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1210\/jc.2002-020299","article-title":"Neurosurgical treatment of Nelson\u2019s syndrome.","volume":"87","author":"Kelly","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614054376800_R11","first-page":"165","article-title":"The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing\u2019s syndrome.","volume":"80","author":"Jenkins","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614054376800_R12","first-page":"647","article-title":"The diagnosis and differential diagnosis of Cushing\u2019s syndrome and pseudo-Cushing\u2019s states.","volume":"19","author":"Newell-Price","year":"1998","journal-title":"Endocr Rev"},{"key":"2020071614054376800_R13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1464-5491.2000.00269.x","article-title":"Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus.","volume":"17","author":"Nolan","year":"2000","journal-title":"Diabet Med"},{"key":"2020071614054376800_R14","author":"Diggle","year":"2002"},{"key":"2020071614054376800_R15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2265.2006.02501.x","article-title":"The PPAR-\u03b3 activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson\u2019s syndrome.","volume":"64","author":"Mullan","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614054376800_R16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/eje.1.01994","article-title":"Rosiglitazone for prevention or adjuvant treatment of Nelson\u2019s syndrome after bilateral adrenalectomy.","volume":"153","author":"Andreassen","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"2020071614054376800_R17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2265.2006.02610.x","article-title":"PPAR-\u03b3 expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-\u03b3 receptor.","volume":"65","author":"Emery","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614054376800_R18","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors.","volume":"89","author":"Pivonello","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614054376800_R19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1172\/JCI11098","article-title":"Retinoic acid prevents experimental Cushing syndrome.","volume":"108","author":"Paez-Pereda","year":"2001","journal-title":"J Clin Invest"},{"key":"2020071614054376800_R20","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/en.2006-0414","article-title":"Retinoic acid as a novel medical therapy for Cushing\u2019s Disease in dogs.","volume":"147","author":"Castillo","year":"2006","journal-title":"Endocrinology"},{"key":"2020071614054376800_R21","author":"Boscaro","year":"2005"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/5\/1758\/9053312\/jcem1758.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/5\/1758\/9053312\/jcem1758.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:23:31Z","timestamp":1594949011000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/5\/1758\/2598513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,1]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2006-2005","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,1]]}}}